advanced search

Kedalion Therapeutics

Kedalion Therapeutics, acquired by Novartis in 2022, was a clinical-stage ophthalmic drug delivery company developing the AcuStream technology. The device’s horizontal stream delivers topical ocular drugs precisely and accurately, aiming to reduce required dose compared with standard drops.


Authors and Contacts

Reynaldo Quintana
Vice-President of Engineering

 

Dr Mark Blumenkranz
Executive Chairman and Co-founder

 

Ehud Ivri
Chief Technology Officer and Co-founder

 

Dr Peter Noymer
Chief Executive Officer

Article

OCULAR
Dr Peter Noymer
ACUSTREAM™: BRINGING TOPICAL OPHTHALMIC DRUG DELIVERY INTO THE MODERN ERA
Peter Noymer, Ehud Ivri, Reynaldo Quintana and Mark Blumenkranz introduce AcuStream, a novel device for next-generation delivery of topical ophthalmic delivery via an aim-assisted stream.
Top